Last reviewed · How we verify

NCT05031026

Dexmedetomidine to Prevent Hepatic Ischemia-reperfusion Injury-induced Glycocalyx Degradation and Early Allograft Dysfunction in Liver Transplantation

Active, enrolled Phase 4 Last updated 2 October 2025
What this trial tests

Phase 4 trial testing Dexmedetomidine in Liver Transplant; Complications in 60 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
15 March 2022
Primary endpoint
15 December 2025
15 February 2026

Quick facts

Lead sponsorAssiut University
PhasePhase 4
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposeprevention
Enrollment60
Start date15 March 2022
Primary completion15 December 2025
Estimated completion15 February 2026
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Assiut University

Who can join

Adults 18 to 60, any sex, with Liver Transplant; Complications. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

the aim of the study is to approve the hypothesis that dexmedetomidine can protect against glycocalyx degradation induced by hepatic ischemia-reperfusion injury and hence can reduce the subsequent complications as early allograft dysfunction, other organ dysfunction and hemodynamic instability

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Dexmedetomidine

Trials testing the same drug.

Other recruiting trials for Liver Transplant; Complications

Currently open trials in the same condition.

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05031026.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing